Fatty liver disease
Therapeutic area
Endocrinology
Rare disease
No
- Definition
- A reversible condition wherein large vacuoles of triglyceride fat accumulate in liver cells via the process of steatosis.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Fatty liver disease
- Therapeutic area
- Endocrinology
- fatty liver disease
- Atherosclerosis With Diabetes Mellitus and Fatty Liver
- fatty liver
- Fatty Liver , Electroacupuncture, Lipid Profile
- Fatty Liver, Nonalcoholic
- Severity
- Mild
- Endocrinology
- Gastroenterology
Sources for recorded values
- MONDO ID
- MONDO:0004790
- Parent condition
- MONDO:0005154
Related records
Broader conditions (7)
- Digestive system disorder
- Disease
- Disease by body system or component
- Endocrine system disorder
- Hepatobiliary disorder
- Human disease
- Liver disorder
Narrower conditions (6)
- Alcoholic fatty liver disease
- Metabolic dysfunction and alcohol associated liver disease
- Metabolic dysfunction-associated steatohepatitis
- Metabolic dysfunction-associated steatotic liver disease
- NAFLD1
- Visceral steatosis, congenital
Trials (624)
- "Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
- "LiverColor": Machine Learning in Liver Photographs
- 12-Month Once-a-week HIIT Improves Body Adiposity and Liver Fat
- A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Liver Cancer
- A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis
- A Clinical Trial of Chazhu Xiaozhi Decoction Against Non-alcoholic Fatty Liver Disease
- A Clinical Trial of Longqi Jiangzhi Decoction Against Non-alcoholic Fatty Liver Disease
- A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH
- A Hepatitis B With Hepatic Steatosis Study
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- A Metabolomics-based Study to Explore the Mechanism of Remission of Metabolic Syndrome Radical Resection of Colorectal Cancer
- A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH
- A Nutrigenetic Intervention in MASLD
- A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis
- A Pathophysiological Study of the Postprandial Human Liver (PLS)
- A Phase 1 Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers
- A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease
- A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis
- A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH
- A Phase II Study of the Effect of a Low Calorie Diet on Patients Undergoing Liver Resection
Drugs in development (39)
- Acetic acid C-11 Early phase 1
- Amino acids Phase 2
- ASP-9831 Phase 2
- Cannabidiol Phase 2
- Cholic acid Phase 2
- Cilostazol Phase 1
- Cysteamine Phase 1
- D-limonene Early phase 1
- Dapagliflozin Phase 3
- Eplerenone Phase 2
- Esomeprazole Phase 1
- Exenatide Phase 2
- FISH OIL Phase 2
- Ginger Early phase 1
- Hydroxychloroquine Phase 3
- Icomidocholic acid Phase 2
- Icosapent Phase 2
- Lactobacillus acidophilus Phase 1
- Levothyroxine Phase 1
- Maraviroc Phase 2
Other linked drugs (11)
- Canagliflozin
- Choline chloride
- Diacerein
- Empagliflozin
- Entecavir
- Erdosteine
- Glucagon
- Obeticholic acid
- Sodium chloride
- Tenofovir alafenamide fumarate
- Tenofovir disoproxil fumarate